Definium Therapeutics (DFTX) Cash from Financing Activities (2021 - 2026)

Definium Therapeutics (DFTX) has reported Cash from Financing Activities for 6 consecutive years, with $5.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 429.84% year-over-year to $5.3 million; the TTM figure through Mar 2026 stood at $271.6 million (up 219.69% YoY), while the FY2025 annual figure was $267.3 million, up 5.56% from the prior year.
• Cash from Financing Activities retreated to $5.3 million in Q1 2026 per DFTX's latest filing, from $245.9 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $245.9 million in Q4 2025 and bottomed at -$166000.0 in Q1 2022.
• Historically, Cash from Financing Activities has averaged $35.7 million across 5 years, with a median of $3.8 million in 2024.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities slumped 100.18% — and 2024, when it surged 28930.36%.
• Definium Therapeutics' Cash from Financing Activities stood at $416000.0 in 2022, then soared by 523.32% to $2.6 million in 2023, then jumped by 46.82% to $3.8 million in 2024, then soared by 6358.31% to $245.9 million in 2025, then sank by 97.84% to $5.3 million in 2026.
• Business Quant data shows DFTX's Cash from Financing Activities at $5.3 million in Q1 2026, $245.9 million in Q4 2025, and $749000.0 in Q3 2025.